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EVIDENCE OF ACTIVE HERPESVIRUS 6 (VARIANT-A) INFECTION IN PATIENTS WITH
LYMPHADENOPATHY IN BELÉM, PARÁ, BRAZIL
Ronaldo B. FREITAS, Maria R. FREITAS & Alexandre C. LINHARES
SUMMARY
A total of 323 patients with lymphadenopathy were selected in Belém, Brazil, between January 1996 and December 2001, and
screened for the presence of human herpesvirus-6 (HHV-6) IgM- and- IgG antibodies by enzyme-linked immunosorbent assay
(ELISA). When seroprevalence is analyzed by gender, similar rates are found for female (60.6%) and male (55.7%) individuals.
Seventy-seven (23.8%) patients were HHV-6-IgM-and- IgG-positive (IgM+ subgroup), with positivity rates of 29.7% and 17.7% (p
= 0.0007) for female- and male individuals, respectively. Sera from a subgroup (n = 120) of these subjects, with high HHV-6 antibody
levels (either IgM+ or IgG+ reactivities), were subsequently processed for the presence of HHV-6 DNA by polymerase chain reaction
(PCR)/nested PCR. Active infections (IgM+ and/or IgG+ high levels specific antibodies plus detection of viral DNA) were diagnosed
in 20/77 (20.0%) and 8/43 (18.6%); subgroup of the 120 individuals suspected of having HHV-6 suggestive recent infection. All (n
= 28) cases of active infection were found to be associated with HHV-6 variant-A (HHV-6A), as detectable by PCR/nested PCR,
using variant-specific primer that amplify regions of 195 base pairs (bp) (HHV-6A) and 423 bp (HHV-6B). Rates of HHV-6 DNA
detection between female and male patients were similar (p > 0.05) in the IgM+ and IgG+ groups: 20.4% versus 35.7% and 25.0%
versus 13.0%, respectively. HHV-6 DNA was detected across ≤ 5 through 41-50-year age-groups for patients whose serum samples
were IgM+, with rates ranging from 7.7% (female subjects aged ≤ 5 years) to 80.0% (male, 11-20 years). Among patients whose
serological status was IgG+, HHV-6 DNA was detected in ≤ 5, 6-10, 21-30 and > 50 age-groups at rates that ranged from 15.4%
(male, ≤ 5 years of age) to 100.0% (female aged 11-20 years). Swelling cervical lymph nodes were the most common sign, accounting
for 9 (32.0%) cases in each gender group. Among patients (n = 28) with active infection by HHV-6A variant, duration of symptoms
lasted 1-5 days in 35.7% of subjects, whereas in 64.3% of them the disease lasted 6-20 days. Our data suggest that it is worth seeking
for HHV-6 infection whenever a patient (infant or adult) presents with lymphadenopathy as a prominent symptom in the course of an
acute febrile illness.
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INTRODUCTION
Human herpesvirus-6 (HHV-6) is largely recognised as an ubiquitous
virus that infects most persons up to the age of 2 years46. It was first
isolated in 1986 by SALAHUDIN et al.50, from patients with
lymphoproliferative disorders or acquired immunodeficiency syndrome.
HHV-6 composes the Roseolovirus genus of the betaherpesvirus
subfamily19,49. Two distinct variants (HHV-6A and HHV-6B) are currently
recognised, with different genetic, biological and immunological
properties1,19. The HHV-6B appears to be isolated more frequently than
HHV-6A from blood, except in patients with AIDS2.
While HHV-6A has been obtained primarily from adults with chronic
illnesses1,5, HHV-6B strains have mostly been isolated from infants with
exanthem subitum (ES) (roseola infantum, sixth disease) and other
paediatric febrile illnesses, including lymphadenopathy18,31,48,52. Since
virtually all children become infected early life, primary HHV-6 infections
among adults are rare events. Whenever these latter conditions occur,
however, clinical findings such as lymphadenopathy38,44,53, heterophile-
negative mononucleosis3,45 and hepatitis21 are likely to result. In most of
the primary infections by HHV-6 the clinical symptoms are high fever
and a rough skin rash, that is, the typical exanthema subitum; convulsions
may also be present in those more severe cases. Primary infection in
adults is not yet fully characterised, but a variety of clinical conditions
have been described, including lymphoproliferative disorders6,7. On the
other hand, reactivation may cause severe disease in immunocom-
promised patients and has also been reported to occur without symptoms
in immunocompetent individuals26. The HHV-6A variant was found to
be the predominant variant present in the lymph node biopsies from the
HIV-infected patients15,34 .
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In vivo HHV-6 replication has been demonstrated in a variety of
cells including lymphocytes, macrophages, histiocytes, and endothelial/
epithelial cells; CD4+ lymphocytes appear to be the main target cells for
HHV-69,10,13,43,44. The frequent detection of HHV-6 antigen/DNA in
salivary glands22,36, lymph node tissues38, neurons and glial cells of the
brain12 suggests that HHV-6 can either persistently infect cells or establish
latency with potential subsequent reactivation. It has been reported that
saliva is likely to play a major role in horizontal transmission of HHV-6,
leading to the widespread of viral infection30. Consequently, serological
studies have in general shown that nearly 100% of infants become infected
before the age of 3 years8,46. In addition to this, large serosurveys
conducted elsewhere, reported HHV-6 seroprevalence rates of 80 to 95%
in healthy adolescents and adults40,51,59. In Northeastern Brazil, HHV-6
seroprevalence rates of 76.5% - 77.2% were reported by LINHARES et
al.41 among Brazilian and Japanese immigrants. Similar surveys were
subsequently conducted in the Amazon region of Brazil, yielding
prevalence rates that ranged from 5.4% to 14.9% among Amerindians25,
and from 75.0% to 100.0% in urban communities23 .
This study focussed on cases of lymphadenopathy occurring in
Belém, Pará, Brazil for which a diagnosis could not be achieved following
a routine screening for those potentially most common causative
infectious agents of this clinical condition. Further assays were then
extended to HHV-6 and specific results are discussed herein.
MATERIALS AND METHODS
This was a retrospective study in which serum samples obtained
from 323 patients with lymphoproliferative syndromes were examined
for HHV-6 infection. These subjects had been referred by local physicians
to the Virology Section of Instituto Evandro Chagas, Belém, Brazil,
during the period of January 1996 to December 2001 for serological
diagnosis. Patients enrolled in this study (n = 323) were selected from a
total of 4,154 subjects with fever and lymphadenopathies who tested
negative for the following agents: rubella, cytomegalovirus, Epstein-
Barr virus, Toxoplasma gondii, and Brucella spp. All patients presented
with an acute disease of moderate severity, mainly characterised by fever
and lymphadenopathy. We did not include those patients with skin rash,
as well as those lymphoproliferative disorders affecting immuno-
suppressed individuals. Study subjects (of whom 165 were female) were
aged between 6 months and 78 years (mean, 19 years) at the time of
blood sampling. Acute-phase blood samples were taken at presentation
to the Institute, and sera were kept frozen at -20 °C until they were
processed.
The detection of IgM and IgG antibodies to HHV-6 was performed
using a commercial enzyme-linked immunosorbent assay (ELISA)
developed by PANBIOTM (East Brisbane, Australia). This is a system
that includes solid-phase wells coated with HHV-6-infected cells,
essentially as described elsewhere4,16,47. For the determination of HHV-6
immunoglobulin M (IgM) sera were tested at single 1:100 (v/v) dilutions,
with previous removal of IgG. This eliminates the interference
phenomenon if rheumatoid factor is present in serum. All samples
yielding optical density (OD) values which are at least twice the mean
absorbance of the “cut off” were regarded as suggestive of recent HHV-
6 infection; this corresponds to > 20 IgM PANBIO units. A subgroup (n
= 120) of subjects among study patients with HHV-6 IgM+ (> 20
PANBIO units for IgM) or IgG+ (≥ 50 PANBIO units for IgG) results
were selected for HHV-6 DNA detection using a two-step polymerase
chain reaction (PCR), as reported before35,53. First amplification was
carried out using a mixture of external oligonucleotides primers
designated as EX1 and EX2, followed by a second amplification cycle
(the nested PCR) that includes a mixture of internal primers IN3 and
IN4. A mixture including 1.5 mM MgCl2, 0.5 µM of each primer, 2.5
units of Taq DNA polymerase (GIBCO-BRL) in the final concentration.
Temperatures were used as follows: one initial cycle at 94 ºC for 5 min,
40 cycles of denaturalization at 94 ºC for one min, annealing at 55 ºC for
one min, and extension at 72 ºC for 1.5 min, with a single final extension
step at 72 ºC for five min. Active HHV-6 infections were defined as the
presence of IgM or/and high IgG antibody levels (≥ 50 PANBIO units)
plus DNA detection.
Variant-specific primers were used for PCR/nested PCR
amplification, targeting two distinct regions of the HHV-6 genome of
195 bp and 423 bp for variants A and B, respectively57.
Conventional ELISA and immunofluorescence indirect assays were
used for the detection of both IgM and IgG to rubella, Epstein-Barr
virus, cytomegalovirus and Toxoplasma gondii, as described
before11,14,17,37. Only 28 samples were tested by standard seroagglutination
to detect Brucella spp antibodies.
Statistical analysis was done with EPI-INFO software, version 6.0
(Atlanta, GA, USA). Comparison of rates between groups was made
with the Mantel-Haenszel chi-square test of association or, if assumptions
required for the chi-square test were not met, with Fisher’s exact test.
Siqnificance was defined as p < 0.05.
RESULTS
Overall, 188 (58.2%) of the 323 patients had HHV-6-specific IgM
and/or IgG antibodies in their sera, whereas 135 (41.8%) subjects were
found to be IgM- and- IgG-seronegative (Table 1). Serological status as
defined by IgG+ was identified in 111 patients. Similar rates of HHV-6
antibodies (IgM and/or IgG) were noted for female and male subjects:
60.6% versus 55.7%, respectively. Seventy-seven (23.8%) patients were
HHV-6 IgM- and- IgG-positive (IgM+ subgroup), with positivity rates
of 29.7% and 17.7% (p = 0.0007) for female- and- male individuals,
respectively. No significant differences (p > 0.05) across ≤ 5 through
41-50-year age-groups were noted when prevalence rates of HHV-6 IgM+
antibodies for female and male subjects are compared. Seropositivity
rates also did not differ significantly when gender groups are compared
for HHV-6 IgG+ patients aged ≤ 5 years and 11-20 to > 50 years; a
significant difference (p = 0.04) was observed between female and male
patients belonging to the 6-10-year age-group. Sera from 120 patients
with presumptive recent infections with IgM+ (n = 77) or IgG+ (n = 43)
specific antibodies, were assessed for the presence of viral DNA by PCR
and nested-PCR, as demonstrated in Table 2. HHV-6 DNA was amplified
from the serum of 20/77 (25.9%) IgM+ patients and from 8/43 (18.6%)
subjects whose serum samples reacted IgG+. There was no statistically
significant difference (p > 0.05). Rates of HHV-6 DNA detection between
female and male patients were similar (p > 0.05) in the IgM+ and IgG+
groups: 20.4% versus 35.7% and 25.0% versus 13.0%, respectively.
HHV-6 DNA was detected across ≤ 5 through 41-50-year age-groups
for patients whose serum samples were IgM+, with rates ranging from
7.7% (female subjects aged ≤ 5 years) to 80.0% (male, 11-20 years).
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Table 2
Distribution of active HHV-6 infections associated with lymphadenopathies, according to sex and age. Belém, Brazil, 1996-2001
Age(years)/sex Total * IgM+ (%) Total IgG+** (%)
tested DNA+ DNA- tested DNA+ DNA-
≤ 5 F 13 1(7.7) 12(92.3) 10 3(30.0) 7(70.0)
M 8 1(12.5) 7(87.5) 13 2(15.4) 11(84.6)
6-10 F 10 5(20.0) 5(50.0) 4 1(25.0) 3(75.0)
M 6 1(16.7) 5(83.3) 5 0(0) 5(100.0)
11-20 F 10 2(20.0) 8(80.0) 3 0(0) 3(100.0)
M 5 4 (80.0) 1(20.0) 0 0(0) 0 (0)
21-30 F 7 1(14.3) 6(85.0) 1 1(100.0) 0(0)
M 3 0(0) 3(100.0) 3 0(0) 3(100.0)
31-40 F 2 1(50.0) 1(50.0) 0 0(0) 0 (0)
M 2 1(50.0) 1(50.0) 0 0(0) 0(0)
41-50 F 5 0 (0) 5(100.0) 2 0(0) 2(100.0)
M 4 3 (75.0) 1(25.0) 0 0(0) 0(0)
> 50 F 2 0 (0) 2(100.0) 0 0(0) 0(0)
M 2 0 (0) 0(0) 2 1(50.0) 1(50.0)
Subtotal F 49 10 (20.0) 39(79.6) 20 5(25.0) 15(75.0)
M 28 10 (35.7) 18(64.3) 23 3(13.0) 20(86.9)
Total 77 20 (26.0)a 57(74.0) 43 8(18.6)b 35(81.4)
* A total of 203 serum samples not screened by PCR/nested PCR.; **IgG detection (≥ 50 Panbio units); a + b = 44.6% (overall percentage of active HHV-6 infections)
Table 1
Detection of antibodies to HHV-6 in patients with lymphadenopathies. Belém,
Brazil, 1996-2001
Serological status, n (%)
Age(years)/sex Total IgM+ * IgG+ IgM-IgG-
tested
≤ 5 F 44 13(29.5) 19(43.2) 12(27.3)
M 46 8(17.4) 19(41.3) 19(41.3)
6–10 F 28 10(35.7) 7(25.0)c 11(39.3)
M 36 6(21.4) 18(50.0)d 12(33.3)
11-20 F 26 10(38.5) 10(38.4) 4(23.5)
M 17 5(29.4)d 8(47.1) 4(23.5)
21-30 F 24 7(29.2) 4(16.7) 13(54.2)
M 16 3(18.8) 3(18.8) 10(41.7)
31-40 F 14 2(14.3) 1(7.1) 11(78.6)
M 15 2(13.3) 3(20.0) 10(66.7)
41-50 F 17 5(29.4) 7(41.2) 5(29.4)
M 18 4(22.2) 4(22.2) 10(55.6)
> 50 F 12 2(16.7) 3(25.0) 7(58.3)
M 10 0(0.0) 5(50.0) 5(50.0)
Subtotal F 165 49(29.7)a 51(30.9) 65(39.4)
M 158 28(17.7)b 60(38.0) 70(44.3)
Total 323 77(23.8)e 111(34.4)f 135(41.8)
 *IgM detection (> 20 Panbio units); a vs b Significant difference between the
results (p = 0.0007); c vs d Significant difference between the results (p = 0.04); e
+ f = 58.2% (overall seroprevalence rate)
Among patients whose serological status was IgG+, HHV-6 DNA was
detected in ≤ 5, 6-10, 21-30 and > 50 age-groups at rates that ranged
from 15.4% (male, ≤ 5 years of age) to 100.0% (female aged 21-30
years).
Figure 1 shows the anatomical sites of enlarged lymph nodes
observed in 28 patients with active HHV-6 infection, according to sex
and duration of these clinical signs in days. Overall, lymph node swelling
was noted at similar rates in female (15, 53.6%) - and - male (13, 46.4%)
patients with active HHV-6 infection caused by variant A. Reactive
cervical lymph nodes were predominant, affecting 9 (32.0%) patients of
each gender group. In smaller proportions, occipital, retroauricular,
axillary and inguinal enlarged lymph nodes were observed. As for the
duration, symptoms lasted 1-5 days in 35.7% of the individuals, whereas
in 64.3% of them the disease lasted 6-20 days. Figure 2 illustrates the
nested-PCR products with molecular weights matching those for HHV-
6A variant are present for 3 of the 28 serum samples from patients with
active infections. No positive results were obtained from testing sera for
Fig. 1 - Localization and duration of the lymphadenopathies in cases of active HHV-6A
infections, according to sex, in 28 patients. Belém, Brazil, 1996-2001.
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potential pathogens other than HHV-6 that might be involved in aetiology
of the lymphadenopathies.
DISCUSSION
The present analysis of the HHV-6 serological status of n = 323
patients with lymphadenopathy of previously unknown aetiology
provided evidence that this herpesvirus may play a role as a cause for
this clinical condition, as already reported elsewhere3. This assumption
is based on the findings showing that about one-third of these patients
had serological suggestive evidence of recent HHV-6 infection, that is,
their sera reacted either IgM+ or IgG+ (high IgG levels) when tested for
the presence of HHV-6 antibodies by ELISA. The proposed association
between lymphadenopathy and HHV-6 infection in the present study is
strengthened by the detection of HHV-6 DNA, by PCR30,53 in 28 subjects
among 120 patients whose sera were indicative of active HHV-6 infection.
Although focussing on a specific group of patients suffering from
lymphoproliferative disorders, the present study allows for a reappraisal
of HHV-6 seroprevalence in Belém, Pará, Brazil, an issue that has been
assessed in previous local surveys conducted by FREITAS &
LINHARES23. The overall prevalence of HHV-6 antibody in the present
study (58.2%) was found to be lower than that yielded before for the
“normal” population of Belém, Brazil, 90.0%23. Although this may have
occurred by chance, it would be worth considering two other explanations
for such a difference. First, in the previous, “normal” population-based
survey23, an indirect immunofluorescence assay was used that might be
more sensitive than the ELISA employed to assess the serological status
of patients with lymphadenopathy. We do not believe that false-positive
results were obtained when using the IFI, because of the high specificity
of the test used8,51. Second, it could be postulated that a proportion of
selected patients who developed lymphadenopathy had indeed primary
HHV-6 infection. An evidence that might possibly support the “primary
infection” hypothesis is that more than 40% of patients with
lymphadenopathy had no detectable HHV-6 antibodies of either IgM or
IgG classes, in contrast with the only 10% antibody-negative proportion
in the normal population23. Our study showed an overall higher HHV-6
antibody (IgM and/or IgG) rate in female than in male patients with
lymphadenopathy in Belém (29.7% versus 17.7%, p = 0.007), in contrast
with similar prevalence rates achieved when comparing female (90.5%)
and male (89.3%) subjects of a previous “normal population” study in
the same setting. It is likely that women are more frequently exposed to
HHV-6, as a result of their close contact with infants who might develop
ES and, therefore, act as a source of viral transmission to mothers and
care-givers. Excretion of HHV-6 in saliva of infants with ES and their
parents suggests this to be a source for transmission of HHV-6 infection55.
A major finding in our study was the detection of HHV-6A DNA in
sera from patients with lymphadenopathy, a viral variant that has been
associated mainly with active infections among immunocompromised
individuals, namely HIV-positive patients2,7,18,34,42,57. Contrasting with
these findings, our investigation has shown HHV-6A variant to be
associated with apparently immunocompetent individuals. Of note, it
has been reported that immunocompromised and immunocompetent
subjects are usually associated with reactivation28,29 and primary
infections32,45,54, respectively, whatever variant considered. Of note,
latency and later reactivation are both biological properties attributable
to HHV-6A and HHV-6B variants in cells and body tissues6,7,20,38,39. It
seems plausible to point out that the detection of HHV-6 DNA in sera
from our patients support the hypothesis of primary infection53,56. Several
studies2,3,5,45 record that active HHV-6A infection occurs later in life when
compared with HHV-6B infection. Indeed, the latter variant appears to
infect mainly infants younger than 3 years24,33,58. It is noticeable, however,
that this has not invariably happened among our study subjects. On the
other hand, some authors2,18,50 have demonstrated that a peak incidence
of the HHV-6A infection occurs during adolescence and adulthood a
pattern which appears more compatible with that recorded in our
investigation. In this regard, it should be pointed out that HHV-6A
infection appeared to be less frequent in our children aged less than five
years with lymphadenopathy.
Of interest, no cases of neurological disorders – even seizures among
infants – were identified among our patients who were infected with
HHV-6A, in spite of previous reports indicating that such A variant has
a possible greater neurotropism than HHV-6B27. In our investigation,
the cervical lymph nodes were more affected in both sexes, as recorded
in studies conducted elsewhere38,45. Although preliminary, our data
suggest that it would be worth seeking for HHV-6 infection, whenever a
patient (infant or adult) presents with lymphadenopathy as a prominent
symptom in the course of an acute febrile illness.
RESUMO
Evidência de infecção ativa por herpesvírus 6 (variante- A) em
pacientes com linfadenopatia em Belém, Pará, Brasil
Um total de 323 pacientes apresentando linfadenopatia foi
selecionado em Belém, Pará, Brasil, entre janeiro de 1996 a dezembro
de 2001 e, posteriormente, examinado quanto à presença de anticorpos
IgM e IgG para o herpesvírus 6 (HHV-6), utilizando-se a técnica
imunoenzimática (ELISA). Taxas similares são encontradas quando a
soroprevalência é analisada nos indivíduos do sexo feminino (60,6%) e
masculino (55,7%). Setenta e sete (23,8%) pacientes apresentaram
anticorpos IgM e IgG para o HHV-6 (subgrupo IgM+), com taxas de
positividade de 29,7% e 17,7% (p = 0,0007) para indivíduos dos sexos
feminino e masculino, respectivamente. Soros de um subgrupo (n = 120)
desses indivíduos, com altos níveis de anticorpos IgM+ ou IgG+, foram
subseqüentemente processados para detecção do DNA viral do HHV-6,
Fig. 2 - Agarose gel electrophoresis of nested PCR-amplified HHV-6 DNA of 6 serum samples,
with variant-A (195 bp) and variant-B (423 bp) stained with ethidium bromide and
photographed under U.V light. Lanes 1, negative control; lane 2, HHV-6B control; lane 3,
HHV-6A control; lanes 4-6, displays HHV-6A positive sera; M denotes molecular-weight.
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através da reação em cadeia da polimerase (PCR) e do “nested” PCR.
Infecções ativas (detecção de altos níveis de anticorpos IgM+ e/ou IgG+
específicos mais a presença de DNA viral) foram diagnosticadas em 20/
77 (26,0%) e 8/43 (18,6%); subgrupo de 120 indivíduos com quadro
sugestivo de infecção recente por HHV-6. Todos (n = 28) os casos de
infecção ativa foram associados com variante A do HHV-6 (HHV-6A),
detectada pela técnica de PCR/“nested” PCR, utilizando-se “primers”
específicos que amplificam regiões de 195 pares de bases (pb) (HHV-
6A) e 423 pb (HHV-6B).Taxas de detecção do DNA do HHV-6 foram
similares (p > 0,05) em pacientes dos sexos feminino e masculino, no
grupo IgM+ e IgG+ com: 20,4% versus 35,7% e 25,0% versus 13,0%,
respectivamente. A detecção do DNA viral do HHV-6 ocorreu no grupo
etário ≤ 5 até o de 41-50 anos, nos pacientes cujas amostras de soro
apresentaram presença de IgM+, com taxas variando de 7,7% (mulheres
do grupo ≤ 5 anos) a 80,0% (homens, 11-20 anos). Acerca dos pacientes
cujo “status” sorológico foi IgG+, o DNA do HHV-6 foi detectado nos
grupos de ≤ 5, 6-10, 21-30 e > 50 anos, com taxas que variaram de
15,4% (homens, ≤ 5 anos) a 100,0% (mulheres, 11-20 anos). O aumento
dos linfonodos cervicais foi registrado como mais freqüente, ocorrendo
em número de 9 (32,0%) casos, tanto entre indivíduos do sexo masculino
como naqueles do feminino. Entre os pacientes (n = 28) com infecção
ativa pela variante A do HHV-6, a duração dos sintomas em 35,7% deles
foi de 1-5 dias, enquanto em 64,3% durou de 6-20 dias. Nossos dados
sugerem ser importante investigar a infecção pelo HHV-6 entre os
pacientes (crianças e adultos) portadores de linfadenopatia como
manifestação clínica proeminente no curso das doenças agudas febris.
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